Citigroup’s Vir Biotechnology VIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$559K Hold
50,000
– – ﹤0.01% 3702
2026
Q2
$510K Buy
+50,000
New +$476K ﹤0.01% 3891
2025
Q1
– Sell
-38,700
Closed -$284K – 5996
2024
Q4
$284K Buy
+38,700
New +$305K ﹤0.01% 4182
2023
Q1
– Sell
-29,900
Closed -$757K – 5888
2022
Q4
$757K Buy
+29,900
New +$733K ﹤0.01% 2866

Other funds holding VIR

Citigroup's VIR Position: Q3 2026 in Review

Citigroup reduced its Vir Biotechnology (VIR) stake by 65% in Q3 2026, selling an estimated $1.43M and leaving 75,620 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.

Citigroup first reported a position in VIR in Q4 2019 and has held it in 28 quarters since. The position peaked at $11.4M in Q1 2024. 266 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • Citigroup held 75,620 shares of Vir Biotechnology worth $845K as of Q3 2026.
  • Citigroup sold 142,799 Vir Biotechnology shares in Q3 2026, an estimated $1.43M.
  • Vir Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3446 holding.
  • Citigroup first reported a position in Vir Biotechnology in Q4 2019 and has held it in 28 quarters since.
  • Citigroup's Vir Biotechnology position peaked at $11.4M in Q1 2024.
  • 266 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.